Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19-BCMA CAR-T cells (Beijing GoBroad Hospital)
- Development stage
- Unknown
- Lead developer
- Beijing Gaobo Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CD19-BCMA CAR-T cells are an investigational autologous chimeric antigen receptor (CAR) T-cell therapy being developed by Beijing GoBroad Hospital for the treatment of refractory autoimmune diseases. This dual-targeting CAR-T therapy simultaneously targets B-lymphocyte antigen CD19, a marker for B cells, and B-cell maturation antigen (BCMA), which is expressed on long-lived plasma cells. By depleting both B cells and plasma cells, the therapy aims to eliminate the source of pathogenic autoantibodies and reset the immune system. It is currently being evaluated in clinical trials for patients with refractory systemic lupus erythematosus (SLE) with lupus nephritis, systemic sclerosis (SSc), and primary Sjogren's syndrome (pSS) associated with pulmonary artery hypertension.
- Other names
- CD19-BCMA CAR-T cellsCD-19-BCMA CAR-T cellsCD 19-BCMA CAR-T cellsCD19-BCMA CARTCD-19-BCMA CARTCD 19-BCMA CARTCD19/BCMA CAR-T cells
02
Targets
CD19 (B lymphocyte antigen CD19)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on CD19-BCMA CAR-T cells (Beijing GoBroad Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19-BCMA CAR-T cells (Beijing GoBroad Hospital).